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Abstract
Background: Spt7 is an integral component of the multi-subunit SAGA complex that is required
for the expression of ~10% of yeast genes. Two forms of Spt7 have been identified, the second of
which is truncated at its C-terminus and found in the SAGA-like (SLIK) complex.
Results: We have found that C-terminal processing of Spt7 to its SLIK form (Spt7SLIK) and to a
distinct third form (Spt7Form3) occurs in the absence of the SAGA complex components Gcn5, Spt8,
Ada1 and Spt20, the latter two of which are required for the integrity of the complex. In addition,
N-terminally truncated derivatives of Spt7, including a derivative lacking the histone fold, are
processed, indicating that the C-terminus of Spt7 is sufficient for processing and that processing
does not require functional Spt7. Using galactose inducible Spt7 expression, we show that the three
forms of Spt7 appear and disappear at approximately the same rate with full-length Spt7 not being
chased into Spt7SLIK or Spt7Form3. Interestingly, reduced levels of Spt7SLIK and Spt7Form3 were
observed in a strain lacking the SAGA component Ubp8, suggesting a regulatory role for Ubp8 in
the truncation of Spt7.
Conclusion: We conclude that truncation of Spt7 occurs early in the biosynthesis of distinct Spt7
containing complexes rather than being a dynamic process linked to the action of the SAGA
complex in transcriptional regulation.
Background
The multisubunit SAGA (Spt-Ada-Gcn5-Acetyltransferase)
complex is a prototype for transcriptional coactivators
that interface between DNA binding transcriptional regu-
lators, the chromosomal template and the basal transcrip-
tional machinery [1]. SAGA is a dynamic entity, with
components existing in subcomplexes having related but
distinct functions [2-6].
The Ada components of SAGA (ADA2, NGG1/ADA3,
GCN5/ADA4) were first identified based on their involve-
ment in regulated transcription in Saccharomyces cerevisiae
[7-11]. SAGA possesses histone acetyltransferase (HAT)
activity mediated by Gcn5 [2,12], which stimulates or
represses transcription in a promoter specific fashion [13-
17]. The structural core of SAGA is composed of a subset
of the TBP-associated factors (TAFs) that are also found in
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TFIID [18,19]. Spt7, Ada1 and Spt20, members of the
TBP-subclass of Spt (Suppressors of Ty insertions) [2,20-
22] proteins, are located near the core of the complex and
are required for its integrity, forming an interface between
TAFs and other SAGA-specific components [19]. The addi-
tional Spt proteins, Spt3 and Spt8 are involved in direct
interactions with TBP [3,22-25]. Tra1, a 437 kDa, phos-
phatidylinositol-3-kinase related protein [26,27] is found
at the periphery of the complex and interacts with DNA-
binding transcriptional regulators thus conferring pro-
moter specificity to SAGA [28-32]. Through mass spec-
trometry analysis of purified SAGA complex, other
components have been identified [33-36]. One of these
proteins, Sus1, is associated with the nuclear pore mRNA
export machinery [35] suggesting that SAGA may have a
broader role in nuclear processes than previously envi-
sioned.
Two forms of Spt7 have been described. The full-length
protein of 1332 amino acid residues is found within the
SAGA complex [2]. The second, a C-terminally truncated
form likely arising from processing between residues 1125
and 1150 is found in the SLIK (SAGA-like) complex [3-6].
As suggested by the alternate name for this complex,
SALSA (SAGA altered, Spt8 absent), SLIK also differs from
SAGA in that it lacks Spt8 [3,4]. The absence of Spt8 can
be attributed to the fact that it interacts with Spt7 in the
region deleted in the truncated form [4,6]. The truncation
of Spt7 and the subsequent loss of Spt8 may be a mecha-
nism to create a complex that acts without effects medi-
ated through TBP; for example, the derepression of the
HIS3 promoter under starvation conditions [3,4]. A fur-
ther difference between SAGA and SLIK is that Rtg2, which
is required for the retrograde response pathway in yeast
[37], is found specifically in SLIK [5]. Two other Rtg pro-
teins, Rtg1 and Rtg3 are transcription factors required for
the expression of retrograde target genes such as CIT2
[38]. Pray-Grant et al. [5] propose that SLIK facilitates
transcriptional activation by Rtg1 and Rtg3 and perhaps
also at a distinct set of promoters. However, the exact role
of SLIK is unclear as the interpretation of transcriptional
effects upon disruption of RTG2 is complicated since Rtg2
is required for nuclear import of Rtg1 and Rtg3 [39].
Two models for the relationship between the Spt7-con-
taining complexes can be envisioned. In the first, process-
ing at the C-terminus would occur as part of the
biosynthesis of distinct SAGA and SLIK complexes. Alter-
natively, processing might occur during the normal func-
tioning of SAGA, perhaps to irreversibly signal that a
transcriptional event had occurred and/or enabling subse-
quent activity of the SLIK complex. In this study we per-
formed experiments to differentiate between these
models. We show that the conversion of Spt7 from its full-
length SAGA-form (Spt7SAGA) to its truncated SLIK-form
(Spt7SLIK) and a third C-terminally processed form
(Spt7Form3) occurs in the absence of components of the
complex including Ada1 and Spt20, which are required
for the integrity of the complex. Processing to these forms
occurs rapidly after its synthesis and in the absence of full-
length Spt7. Taken together our results suggest that
processing of Spt7 occurs in the biosynthesis of distinct
Spt7-containing complexes.
Results and discussion
Truncated forms of Spt7 occur in the absence of fully 
functional SAGA complex
Two forms of Spt7 have been described that differ in their
length [3-6]. Full-length Spt7 is 1332 amino acid residues
and is found in the SAGA complex. This form, Spt7SAGA,
migrates with an apparent molecular mass of approxi-
mately 200 kDa on SDS-PAGE. The SLIK complex con-
tains a C-terminal truncation of Spt7 that results in an
apparent molecular mass of approximately 180 kDa [4].
Based upon the mobility of this form and the differential
function of Spt7 derivatives with C-terminal deletions,
Spt7SLIK is predicted to contain a C-terminal truncation of
approximately 200 amino acids [4,6]. To detect these
forms of Spt7 we engineered a centromeric plasmid
expressing a TAP and Flag-tagged version of Spt7 that
could be identified after C-terminal truncation (YCpDed-
TAP-Flag-SPT7, Figure 1a). We first addressed whether this
molecule was functional by determining if it would com-
plement a deletion of spt7 as assayed by growth on media
depleted for inositol. As shown in Figure 1b, a strain lack-
ing SPT7 is unable to grow on media lacking inositol.
YCpDed-TAP-Flag-SPT7 allows for near complete restora-
tion of growth.
To determine if the components of the SAGA or SLIK com-
plex influence the truncation of Spt7, we introduced YCp-
Ded-TAP-Flag-SPT7 into yeast strain BY4741 (wild-type)
and isogenic strains deleted for GCN5, RTG2, SPT8, UBP8,
ADA1 and SPT20. Cells were grown in YPD media and
protein extracts examined for Spt7 by Western blotting
with anti-Flag antibody (Figure 2a). Two proteins with
apparent molecular masses of approximately 220 and 200
kDa were present in wild-type cells containing YCpDed-
TAP-Flag-SPT7 but not in control cells (compare lanes 1
and 2). The size of these molecules suggest that they rep-
resent the TAP-Flag tagged full-length (Spt7SAGA) and
SLIK-forms (Spt7SLIK) of Spt7. The ratio of SAGA:SLIK
forms of Spt7 was ~3:1 in the wild-type strain BY4741
(lane 2). This relative amount of Spt7SLIK was not reduced
upon disruption of GCN5, RTG2, ADA1, SPT20 or SPT8.
Since Spt20 and Ada1 are required for the integrity of the
SAGA complex [6], the presence of Spt7SLIK in these dele-
tion strains indicates that C-terminal processing can occur
in the absence of the fully intact and functional complex.
(We do note that there was an apparent decrease in theBMC Biochemistry 2007, 8:16 http://www.biomedcentral.com/1471-2091/8/16
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ratio of SAGA:SLIK forms in the spt20∆0 strain and specu-
late that this may be due to differential stability of the
forms in this strain background.) In addition, the wild-
type level of Spt7SLIK seen in the spt8 deletion background
suggests that the Spt8 interaction with Spt7 does not alter
access of the putative processing enzyme(s) to the cleav-
age site. Furthermore, the lack of a requirement for Rtg2
indicates that the SLIK complex need not fully assemble to
allow truncation of Spt7.
Although still apparent, the amount of Spt7SLIK  was
reduced approximately three-fold in the strain deleted for
the ubiquitin protease Ubp8 (Figure 2a, lane 6). We note
that the ubp8∆0 effect was found to vary from approxi-
mately two-fold to five-fold between different experi-
ments (not shown). To determine whether the role of
Ubp8 was the result of its involvement with SAGA, we
examined the Spt7 forms in a strain deleted for Sgf11, a
subunit of SAGA required for the association of Ubp8
with components of the complex [40-42]. As shown in
Figure 2b, deletion of sgf11 partially reduced the level of
Spt7SLIK. This effect was not to the same extent as deletion
of Ubp8, perhaps because low levels of Ubp8 remain asso-
ciated with SAGA in the absence of Sgf11 [40]. Nonethe-
less, while not eliminating other mechanisms, the result is
consistent with a model whereby binding of Ubp8 to
SAGA may alter the accessibility of the C-terminus of Spt7
to cleavage. Interestingly, another Flag-antibody reactive
band, Spt7Form3, was evident in the sample lanes but not
in the control. Since Spt7Form3 was somewhat obscured by
a Flag antibody cross-reactive band, we analyzed the Spt7
forms in different strain backgrounds after first purifying
TAP-Flag-Spt7 on IgG-agarose (Figure 2c). After purifica-
tion a Flag-reactive molecule with an apparent mass
approximately 20 kDa less than Spt7SLIK (also see Figure
3b) was revealed. The observed difference in mass of this
molecule relative to intact Spt7 estimates an end-point at
approximately amino acid residue 950. As was the case for
Spt7SLIK, the level of this third form of Spt7 was compara-
ble in each of the deletion strains (gcn5∆0,  spt8∆0,
spt20∆0, ada1∆0, rtg2∆0) with the exception of ubp8∆0
where it was reduced.
C-terminal processing of Spt7 occurs in the absence of its 
N-terminal amino acid residues
The finding that Spt7SLIK and Spt7Form3 were formed in the
absence of components of SAGA, including Spt20 and
Ada1, suggested that processing is not linked directly to
the activity of the complex. If processing were part of the
functional dynamics of SAGA, that is, occurring as a result
of its activities in the regulation of transcription, then one
would predict that it would require Spt7 in a functional
form. We thus examined whether N-terminal deletion
derivatives of Spt7, expressed in BY3218 (spt7∆0) would
be processed (Figure 3). Each molecule was N-terminally
TAP and Flag tagged to allow purification and identifica-
tion of Spt7 forms. The two longest derivatives (residues
580–1332 and 873–1332) contain the elements of the
protein required for partial function [6]. By comparison,
the shortest derivative (residues 1038–1332) lacks the his-
tone fold, which is required for interaction with other
components of the complex [43]. A protein reduced by
approximately 20 kDa, an estimated mass consistent with
a truncation at the Spt7SLIK processing site, was seen for
each of the derivatives (denoted as SL). A further trunca-
tion, approximately 20 kDa smaller than Spt7SLIK and
Epitope-tagged Spt7 molecules used in this study Figure 1
Epitope-tagged Spt7 molecules used in this study. A TAP-Flag-Spt7 contains N-terminal TAP and Flag tags fused in frame to the ini-
tiator Met of Spt7 (1332 amino acids) via a triple alanine linker encoded by a NotI site. Myc-Spt7 has a similar constructed N-
terminal myc-epitope while Flag3-Spt7 contains 3 tandem copies of the Flag epitope. The position of the histone fold (amino 
acids 979–1045; [43]) is indicated with inverted arrows. An arrow indicates the approximate position of the cleavage site that 
generates Spt7SLIK. B. TAP-Flag-Spt7 is functional. Yeast strains BY4741 (SPT7), BY3218 (spt7∆0) and BY3218 transformed with 
YCpDed-TAP-Flag-SPT7 were grown on a minimal plate depleted of inositol for 3 days at 30°C.
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Processed forms of Spt7 in yeast deletion strains Figure 2
Processed forms of Spt7 in yeast deletion strains. A. Wild-type (BY4741) or the indicated yeast deletion strains (gcn5∆0, rtg2∆0, 
spt8∆0, ubp8∆0, ada1∆0, spt20∆0; lanes 3–8, respectively) were transformed with YCpDed-TAP-Flag-SPT7, with the exception 
of lane 1 (ctrl) which was transformed with the control vector YCp-TAP-Flag. Cells were grown to an A600 = 1.0–1.5 in YP 
containing 2% glucose and crude cell lysates prepared by glass bead disruption. 50 µg of protein was separated by 5% SDS-
PAGE and Western blotted with anti-Flag antibody. The mobility of a 200 kDa molecular weight marker is indicated on the left. 
Spt7SAGA and Spt7SLIK are marked. B. BY4741 (Wt, lane 2) and the indicated deletion strains (ubp8∆0, lane 3; sgf11∆0, lane 4; 
sgf29∆0, lane 5; sgf73∆0, lane 6) containing TAP-Flag-Spt7 were grown as above, crude yeast extracts separated by SDS-PAGE 
and Western blotted with anti-Flag-antibody. Lane one contains crude extract from the wild-type strain BY4741. Spt7SAGA, 
Spt7SLIK and Spt7Form3 are marked. C. Wild-type (BY4741 lanes 2 and 3) or the indicated yeast deletion strains, gcn5∆0 (lane 4), 
spt8∆0 (lane 5), spt20∆0 (lane 6), ada1∆0 (lane 7), rtg2∆0 (lane 8), ubp8∆0 (lane 9) containing YCpDed-TAP-Flag-SPT7 were 
grown in YP broth containing 2% glucose. Lane 1 (ctrl) contains BY4741 transformed with the control vector YCp-TAP-Flag. 
TAP-Flag-Spt7 was purified through affinity chromatography on IgG-Agarose and eluted after cleavage with TEV protease. 
Approximately equal amounts of Spt7 were separated by 5% SDS-PAGE and Western blotted with anti-Flag antibody. The 
mobility of 250 and 150 kDa molecular mass markers are indicated on the left. Lane 3 contains one half of the wild-type sample 
applied in lane 2 to facilitate quantitation.
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Formation of truncated forms of Spt7 in N-terminally deleted derivatives Figure 3
Formation of truncated forms of Spt7 in N-terminally deleted derivatives. A. N-terminally deleted derivatives of Spt7 were con-
structed containing amino acids 581–1332 (Spt7581–1332), 873–1332 (Spt7873–1332) and 1038–1332 (Spt71038–1332). Note that each 
molecule is N-terminally TAP and Flag tagged to allow purification then detection of processed fragments. The position of the 
histone fold is shown with a black box and the approximate position of the Spt7SLIK and Spt7Form3 processing sites by arrows. B. 
YCpDed-TAP-Flag- Spt7581–1332, Spt7873–1332 and Spt71038–1332 were expressed in BY3218 (spt7∆0), tandem affinity purified and 
Spt7 forms detected by Western blotting with anti-Flag antibody after electrophoresis on an 8–15% gradient gel. Mobility of 
protein standards with the indicated molecular masses (kDa) is indicated on the left. Arrows on the right marked with 581, 873 
and 1038 represent the mobility of truncated TAP-Flag- Spt7581–1332, Spt7873–1332 and Spt71038–1332, respectively. * marks an 
additional cleavage product seen with Spt7581–1332.
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potentially corresponding to processing at the Spt7Form3
site (F3), was evident for Spt7581–1332 and Spt7873–1332
(though at a reduced level). Note that the third-form
equivalent was not seen for Spt71037–1332, because its puta-
tive cleavage site is removed from this construct. This
result suggests that the elements required for processing
are intrinsic to the C-terminal end of Spt7 and that the N-
terminus of the protein is not required. Furthermore, the
appearance of a cleavage product for Spt71037–1332 suggests
that processing can take place independently from SAGA
and is thus not linked to the action of the complex. For
Spt7581–1332, a fourth form was apparent just below Form
3 (marked by *). We have not characterized this form fur-
ther and can not exclude that it is a degradation product.
If the forms of Spt7 were created progressively from one
another in response to the activity of the complex, one
would predict that the longer forms would be chased into
shorter forms. We analyzed the appearance and disap-
pearance of the Spt7 forms upon inducing expression of a
triple Flag-tagged Spt7 under control of the GAL10 pro-
moter (GAL-Flag3-Spt7; see Figure 1). As shown in Figure
4a, cells containing GAL-Flag3-Spt7 rapidly induce the
three Spt7 forms when shifted from raffinose to galactose
containing media but not upon shifting to glucose con-
taining media. Figure 4b is a time course of the appear-
ance and disappearance of the Spt7 forms after induction
in galactose containing media and subsequent shift to
media containing glucose. Expression of the forms contin-
ued to increase after promoter shut-off until approxi-
mately the 60 minute time point. All three forms
increased at approximately the same rate. After 60 min-
utes, the amounts of the Spt7 forms began to decay. This
was in contrast to total protein, which continued to
increase (comparing the Western blot versus the stained
gel in Figure 4b). Similar to their appearance, the three
forms disappeared at approximately the same rate. The
longer forms were not chased into the shorter molecules,
suggesting that Spt7SLIK and Spt7Form3 are produced early
after the synthesis of Spt7SAGA and not sequentially as the
result of the action of the complex. Combined with the
results above, processing appears inherent to the C-termi-
nus of the molecule and occurs independently from the
action of the SAGA complex.
Further characterization of the 160 kDa form of Spt7
To eliminate the possibility that the appearance of
Spt7Form3 was related to blotting with Flag antibody or to
the TAP-tag, we expressed N-terminally myc-tagged Spt7,
separated crude protein extract by SDS-PAGE and blotted
with anti-myc antibody (Figure 5a). A band approxi-
mately 20 kDa smaller than myc-Spt7SAGA, likely myc-
Spt7SLIK was present in wild-type cells containing YCp88-
myc-SPT7 but not in control cells (compare lanes 1 and 2)
as was the third-form at an apparent mass of ~160 kDa. To
determine if Spt7Form3 was an artifact of the partial TAP
purification or expression in cells also containing a wild-
type copy of SPT7, we purified TAP-Flag-Spt7 from
BY4741 (wild-type) and BY3281 (spt7∆0) through both
tandem affinity steps, IgG-Agarose and Calmodulin-
Sepharose. As shown in Figure 5b, a ~160 kDa, Flag-
detected protein was apparent after purification (lanes 2
and 4) and not in a mock purification (lanes 1 and 3) in
both strain backgrounds.
To examine if Spt7Form3 is found within complexes, TAP-
Flag-Spt7 was expressed in BY4741 and a crude protein
extract applied to a Superose 6 HR10/30 gel filtration col-
umn. The elution profile of the different forms of Spt7 was
examined by Western blotting with anti-Flag antibody
and the relative amounts of the three forms of Spt7 deter-
mined by densitometry (Figure 5c). All three forms of
Spt7 eluted in fractions corresponding to a high molecular
mass, the largest being Spt7SAGA, followed by Spt7SLIK.
Spt7Form3 eluted from the column with an average appar-
ent molecular size slightly less than Spt7SLIK. To determine
if Spt7Form3 was associated with components of the SAGA
complex, extracts were prepared from strains containing
N-terminally Flag-tagged Spt7 and TAP-tagged versions of
Gcn5, Ada2, Ubp8, Taf5, Spt3 and Spt8. Complexes con-
taining the TAP-tagged molecules were partially purified
and the presence of the different forms of Spt7 analyzed
by Western blotting with anti-Flag antibody (Figure 5d,
lanes 3–9). Identification of the forms was established by
immunoprecipitation of Flag-Spt7 from crude extracts
with anti-Flag antibody (compare lanes 1 and 2). As
expected from the interaction of Spt8 with the C-terminal
end of Spt7 [4,6], Spt8 interacted only with full-length
Spt7 (lane 8). The other SAGA components interacted
with both Spt7SAGA and Spt7SLIK. Spt7Form3 did not co-
purify with the SAGA components to the extent of either
Spt7SAGA or Spt7SLIK.
The function of Spt7Form3  is unknown. The fact that
Spt7Form3 appears as stable as the longer forms is consist-
ent with it having a function(s), likely distinct from com-
ponents of the SAGA complex. It is interesting to note that
Spt7 has been found to associate with Ccl1, Rtf1 and
Prp43, and that these interactions are not reciprocated by
C-terminally TAP-tagged Spt7 or generally by other com-
ponents of the SAGA complex (Saccharomyces Genome
Database). In addition, we previously observed a possible
SAGA-independent form of Spt7 by fractionation of crude
extracts on a Mono Q column [27]. We also must consider
an alternative model, whereby Spt7Form3 is an intermedi-
ate along a pathway of degradation. In this regard, we did
observe an apparent increase in Spt7Form3 during TAP-
purification.BMC Biochemistry 2007, 8:16 http://www.biomedcentral.com/1471-2091/8/16
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Time course of the induction and decay of Spt7 forms Figure 4
Time course of the induction and decay of Spt7 forms. A. CY1811 containing YIplac211-GAL-Flag3-SPT7 was grown in minimal media 
containing 2% raffinose then diluted 1:5 into YP media containing 2% glucose (lane 2) or 2%galactose (lane 3) and grown for 30 
minutes. Extracts were prepared by glass bead disruption and 100 µg separated by SDS-PAGE (5%). Flag3-Spt7 was detected by 
Western blotting with anti-Flag antibody. Lane one contains 100 µg of protein extract prepared after growth of BY4741 in 
galactose-containing media. B. CY1811 containing YIplac211-GAL – Flag3-SPT7 was grown in raffinose. Expression of Spt7 was 
induced by the addition of galactose then inhibited by the addition of YP media containing 2% glucose. Cells were grown for 90 
minutes which was empirically determined as time 0. Additional equal volume samples were taken at time 0, 30, 60, 120 and 
240 minutes (lanes 2–7). Protein extracts were prepared and equal volumes separated by SDS-Page (5%). Flag3-Spt7 was 
detected by Western blotting (top panel) or stained with Coomassie Brilliant Blue (bottom panel).
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Characterization of Spt7 Form3 Figure 5
Characterization of Spt7 Form3. A. YCp88-myc was transformed into BY4741 (lane 1, ctrl) and YCp88-myc-SPT7 into BY4741 
(lane 2). Crude protein extracts were prepared and Western blotted with anti-myc antibody. The mobility of a 160 kDa 
molecular weight marker is indicated. Spt7Form3 is marked as F3. B. BY4741 (wild-type, right panel) and BY3218 (spt7∆0, left 
panel) were transformed with YCpDed-TAP-Flag (lanes 1 and 3) or YCpDed-TAP-Flag-SPT7 into (lanes 2 and 4). Extracts were 
prepared by grinding 1 litre of cells in liquid nitrogen, and subjected to TAP purification. 20 µl of the peak fractions were blot-
ted with anti-Flag antibody. C. Gel filtration chromatography of Spt7 from crude yeast extracts. 8.5 mg of protein extract was pre-
pared from yeast strain BY4741 containing YCpDed-TAP-Flag-SPT7 and applied to a Superose 6 HR10/30 column (Pharmacia). 
500 µl fractions were collected, precipitated with 10% trichloroacetic acid, separated on a 5% SDS-polyacrylamide gel and 
Western blotted with anti-Flag antibody. Relative amounts of each of the three forms as determined by densitometry are 
shown as are the peak fraction for elution of the indicated molecular mass standards. D. Wild-type (4741; lane 9) or strains 
containing C-terminally TAP-tagged Gcn5, Ada2, Ubp8, Taf5, Spt3 and Spt8, expressing Flag-Spt7 (lanes 3–8) were grown in YP 
media containing 2% glucose to an OD600 = 2.0. Twenty-five milligrams of crude lysate was purified on IgG agarose. Bound pro-
tein was separated by 5% SDS-PAGE and Flag-Spt7 forms detected with anti-Flag antibody. To demonstrate the position of the 
three Spt7 forms lanes 1 and 2 are extracts of BY4741 transformed with YCpDed-Flag-SPT7 that have been purified on Sepha-
rose 4B (-'ve) or anti-Flag antibody coupled to Sepharose (Spt7) then Western blotted with anti-Flag antibody. The positions of 
molecular mass markers, Spt7SAGA (SA), SPT7SLIK (SL) and Spt7Form3 (F3) are indicated.
Flag IP
Spt7 -ve
IgG purified
Spt8 Gcn5 Ada2 Ubp8 Taf5 4741
250
SA
Spt3
150
12
F3
8 3456 9 7
SL
SA
SL
F3 160
123 4
Anti-myc Ab A B
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Fraction
SAGA
SLIK
Form 3
670 kDa void 158 kDa
D
e
n
s
o
m
e
t
r
y
C
SA
SL
F3
TAP-Flag Spt7 - + - +
250-
150-
spt7∆0S P T 7
12
DBMC Biochemistry 2007, 8:16 http://www.biomedcentral.com/1471-2091/8/16
Page 9 of 12
(page number not for citation purposes)
Conclusion
In this report we show that processing of the C-terminus
of Spt7 to the form found in the SLIK complex and to a
novel third form does not require a functional SAGA com-
plex. C-terminal truncation occurs in the absence of key
components of SAGA and SLIK complexes. Spt20 and
Ada1 are necessary for the integrity of a complete SAGA
complex with their deletion resulting in severe transcrip-
tional effects [6,22], yet processing occurs in their
absence. In addition, since the truncated Spt7 molecules
were present in a gcn5∆0 strain, histone acetylation is not
required for processing. Also suggesting that processing of
Spt7 is independent of the function of SAGA, we found
that a truncated derivative of Spt7 that lacks the histone
fold is capable of being processed in a strain lacking full-
length Spt7. Finally a time course revealing the appear-
ance and disappearance of the Spt7 forms showed that
Spt7SAGA is not chased into the shorter forms. We thus sug-
gest that processing of Spt7 is an independent event in the
biosynthesis of distinct Spt7 containing complexes rather
than being linked to transcriptional regulation by the
SAGA complex.
Processing of Spt7 showed partial dependence on the
ubiquitin protease Ubp8. The role of Ubp8 is unclear but
based on a partial effect upon deletion of Sgf11, it may
require the association of Ubp8 with SAGA. We were
intrigued by the possibility that the effect of Ubp8 may be
related to our previous observation of the ubiquitylation
of Spt7 dependent on the E3-ubiquitin ligase Tom1 [44];
however, because the relative amounts of the Spt7 forms
appear unchanged in a tom1∆0  strain (not shown) we
have concluded that these observations are unrelated.
Our study has identified a third form of Spt7 with an
apparent molecular mass of ~160 kDa. The identification
of this form with three different tagged derivatives sug-
gests that it is not an artifact of tagging; however, we can
not fully exclude the possibility that N-terminal tagging
results in its appearance. Gel-filtration experiments sug-
gest that Spt7Form3 is found within a complex; albeit, dis-
tinct from SAGA or SLIK. As Spt7 was N-terminally tagged,
the mobility of Spt7Form3 on SDS-PAGE suggests a mole-
cule containing amino acid residues 1 to ~950. Determin-
ing the size of the released C-terminal fragment would
facilitate mapping of the cleavage site; however, we have
been unable to identify this molecule using C-terminally
TAP-tagged Spt7.
Methods
Yeast strains
The wild-type yeast strains BY4741 (MATa his∆0 leu2∆0
met1∆0 ura3∆0) and BY4742 (MATα his∆0 leu2∆0 lys2∆0
ura3∆0) and the consortium constructed isogenic knock-
out strains [45] BY3218 (spt7∆0), BY10809 (ubp8∆0),
BY17285 (gcn5∆0), BY14619 (rtg2∆0), BY12666 (spt8∆0),
BY14433 (sgf73∆0), BY13418 (sgf29∆0), BY2781
(sgf11∆0), BY1038 (ada1∆0) and BY17390 (spt20∆0), and
strains containing C-terminally TAP-tagged SAGA compo-
nents were purchased from Open Biosystems or Research
Genetics. CY1811 is a derivative of BY4741 that contains
a YIplac211-GAL-Flag3-SPT7 integrated at the endogenous
locus.
DNA constructs
YCpDed-TAP is a derivative of the LEU2 containing centro-
meric plasmid YCplac111 [46] that contains a DED1 pro-
moter [9] driving expression of a TAP epitope. The DED1
promoter was synthesized by PCR using oligonucleotides
4149-1 and 4149-2 (see Table 1) and cloned as a PstI-
BamHI fragment into YCplac111. The TAP epitope was
subsequently cloned as a BamHI to SstI fragment into this
molecule after its PCR using oligonucleotides 4149-4 and
4168-1 and pFA6a as the template (kindly provided by
Kathy Gould). The coding sequence for the Flag-epitope
was cloned into this molecule at the engineered NotI site
using oligonucleotides 4213-1 and 4213-2 to give YCp-
Ded-TAP-Flag. Epitope-tagged Spt7 was constructed
through PCR amplification of two tandem parts of the
3999 base pair gene using oligonucleotides 4051-1 and
4051-2 for the 5'-segment and 4009-1 and 4009-2 for the
3'-segment, respectively. The two segments were ligated
using the common internal SalI restriction site and cloned
into YCpDed-TAP-Flag as a NotI-SstI fragment to generate
YCpDed-TAP-Flag-SPT7. A molecule expressing Myc-
tagged Spt7 was constructed by cloning a NotI-EcoRI frag-
ment from YCpDed-Tap-Flag-SPT7 into the URA3 centro-
meric plasmid YCp88-myc [9] to generate YCp88-myc-
SPT7. Single Flag-tagged Spt7 similarly contains a Met-
Tyr-Lys-Asp4-Lys coding sequence inserted directly before
the NotI site.
TAP-tagged derivatives of Spt7 with 752, 460 and 295 C-
terminal amino acids were constructed by PCR using oli-
gonucleotides 4009-1, 4536-1 and 4536-2 as 5' primer,
and 4009-2 as 3' primer. Each was cloned into YCpDed-
TAP-Flag as a NotI-EcoRI fragment to generate YCpDed-
TAP-Flag-SPT7580–1332, YCpDed-TAP-Flag-SPT7872–1332
and YCpDed-TAP-Flag-SPT71038–1332.
The parent construct for plasmids expressing Flag3-Spt7 is
pCB1450. This molecule contains a N-terminal Flag
epitope (engineered with oligonucleotides 2821-1 and
2821-2) flanked upstream by the PstI site of the pUC
polylinker and downstream by a NotI site. Genes to be
expressed can be inserted as NotI-(SacI)EcoRI fragments.
The polylinker HindIII site was deleted allowing insertion
of promoter fragments as PstI-HindIII fragments. The
GAL10 promoter was synthesized by PCR using oligonu-
cleotides 2764-1 and 2764-2 and inserted into pCB1450.BMC Biochemistry 2007, 8:16 http://www.biomedcentral.com/1471-2091/8/16
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SPT7 from YCpDed-TAP-Flag-SPT7 was inserted as a NotI-
EcoRI fragment and two additional Flag epitopes were
inserted at the NotI site using oligonucleotides 4213-1 and
4213-2. For integration into yeast the GAL-Flag3-SPT7
module was inserted into YIplac211 [46]. Integration into
the endogenous locus was possible after digestion with
SalI.
TAP purification
Tandem affinity purification (TAP) was carried out as
described [47] with minor modifications. Yeast cells were
grown in YPD to an A600 = 1.5 and lysed by grinding in liq-
uid nitrogen [48]. All further steps were performed at 4°C.
Per liter of starting culture, cell extracts were suspended in
~5 ml of IPP150 (10 mM Tris-HCl (pH 8.0), 150 mM
NaCl, 0.1% NP-40) with protease inhibitors (1 mM
PMSF, 0.1 mM benzamidine hydrochloride, 2 µg/ml pep-
statin A, 2 µg/ml leupeptin and 0.1 mg/ml trypsin inhibi-
tor). The extract was cleared by centrifugation at 40,000 g
for 1 h and incubated with 400 µl of IgG-Agarose (Sigma-
Aldrich Canada Ltd) suspension for 2 h. After washing
with 30 ml of IPP150 and 10 ml of TEV cleavage buffer
(10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5 mM EDTA,
1 mM dithiothreitol, 0.1% NP-40), IgG beads were sus-
pended in 1 ml of TEV cleavage buffer and incubated with
~100 U TEV protease for 2 h. 3 µl of 1 M CaCl2 was added
to the TEV-cleaved eluent which was then diluted with 3
ml of calmodulin binding buffer (10 mM Tris-HCl (pH
8.0), 150 mM NaCl, 1 mM magnesium acetate, 1 mM imi-
dazole, 2 mM CaCl2, 1 mM beta-mercaptoethanol, 0.1%
NP-40). For the second step of purification the protein
was applied to 400 µl of Calmodulin-Sepharose (Strata-
gene Inc) and incubated for 2 h. After the calmodulin
beads were washed with 30 ml of calmodulin binding
buffer, bound protein was eluted with calmodulin elution
buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM
magnesium acetate, 1 mM imidazole, 20 mM EGTA, 1
mM beta-mercaptoethanol, 0.1% NP-40), in 200 µl frac-
tions. 20 µl of the peak fractions were separated by 5%
SDS-PAGE and subjected to Western blotting.
Western blotting
Yeast extracts were prepared by glass bead disruption [9]
or grinding in liquid nitrogen [48]. Protein was separated
by SDS polyacrylamide gel electrophoresis, transferred to
PVDF membranes (Roche Applied Science) using a wet
transfer system (Bio-Rad) in 48 mM Tris, 40 mM glycine,
0.0375% (6.5 mM) SDS and 20% methanol for 1 h at 100
V and detected using a 20% solution of Immobilon West-
ern (Millipore Corp). Anti-Flag antibodies (M2, Sigma-
Aldrich Canada Ltd) were used at a ratio of 1:4000; anti-
myc antibody (Myc1-9E10 cell line) was used at a ratio of
1:2000. Densitometric scanning of films was performed
using AlphaImager 3400 software (Alpha Innotech, Inc).
Serial dilutions of samples were analyzed to provide
standard curves for suitable film exposure.
Time course of the induction and decay of Spt7
A 10 ml culture of CY1811 was grown to an A600 ~3.0 in
minimal media containing 0.6% casamino acids (Difco)
and 2% raffinose. The culture was diluted with 10 ml of
prewarmed media containing 2% galactose and grown for
30 minutes at 30°C. 80 ml of YP media containing 2%
glucose was added and the cells grown for 90 minutes.
This became time 0, and a 15 ml sample was taken. Cells
were pelleted by centrifugation, washed in ice-cold water
and frozen at -80°C. Additional samples were taken after
30, 60, 120 and 240 minutes. Yeast extracts were prepared
by glass bead disruption in 20 mM Hepes-NaOH (pH
8.0), 240 mM NaCl containing protease inhibitors. Equal
volumes were separated by SDS-PAGE (5%) and Western
blotted with anti-Flag antibody.
Table 1: Oligonucleotides used in this study
Oligo# Sequence (5'-3') Construct(s)
4009-1 GCGGCCGCTGGAAGAAAAGGATTGAATATGG 3' fragment of SPT7
4009-2 GAATTCTATTCAACTATTTAGCGCGCTC
4051-1 GCGGCCGCAATGACTGAAAGAATACCAATAAAG 5'fragment of SPT7
5051-2 CCAAATCGTCTCTATCGTCATCC
4536-1 GATGCGGCCGCGATGGAAGACGCTTCCGTG 5' truncations of SPT7
4536-2 GATCGGCCGCCGGTATCAACAGGCCAGAC
4213-1 GGCCGACTACAAGGACGACGATGACAAGGC N-terminal Flag epitope
4213-2 GGCCGCCTTGTCATCGTCGTCCTTGTAGTC
4149-4 GAGCTCGCGGCCGCATAATCAAGTGCCCCGGAG TAP-tag
4168-1 GGATCCATGAAAGCTGATGCGCAACAAATT
4356-1 GATGCGGCCGCGATGGAAGACGCTTCGTG DED1 promoter
4356-2 GATGCGGCCGCCGGTATCAACAGGCCAGAC
2764-1 AACTGCAGTAATACGCTTAACTGCTC GAL10 promoter
2764-2 CCCAAGCTTGACGTTAAAGTATAGAGGT
2821-1 ACGAAGCTTACCATGGACTACAAGGACGACGAT Met-Flag tag
2821-2 TTGAGCTCTGCGGCCGCCTTGTCATCGTCGTCCBMC Biochemistry 2007, 8:16 http://www.biomedcentral.com/1471-2091/8/16
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Gel-filtration chromatography
Approximately 8.5 mg of whole cell extract from BY4741
containing YCpDed-TAP-Flag-SPT7  was prepared in 40
mM Tris-HCl (pH 7.7), 300 mM NaCl, 0.1% Nonidet P-
40 and 10% glycerol, and subsequently applied to a
Superose 6 HR10/30 column (Pharmacia Inc) at a flow
rate of 0.3 ml/min. Protein from 250 µl aliquots of 500-µl
selected fractions were precipitated with 10% trichloro-
acetic acid, acetone washed, resuspended in SDS loading
buffer and separated on a 5% SDS-polyacrylamide gel.
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